WASHINGTON — President Donald Trump introduced Friday that 9 main pharmaceutical corporations have agreed to slash costs on a variety of prescribed drugs, delivering what the White Home described as probably the most important progress so far in implementing Most-Favored-Nation pricing for American sufferers.
“I’m thrilled to be joined by the leaders of 9 of the world’s largest pharmaceutical producers to announce that they’ve agreed to supply a lot of their flagship medication at closely discounted, Most Favored Nation costs,” Trump mentioned.
The agreements with Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will align U.S. costs with the bottom supplied in different developed nations for drugs treating diabetes, rheumatoid arthritis, a number of sclerosis, bronchial asthma, COPD, hepatitis, HIV and varied cancers.
BREAKING: President Trump introduced an settlement with 9 of the world’s largest pharmaceutical corporations to supply sure flagship prescribed drugs within the U.S. at “most favored nation” costs, matching the bottom charges charged overseas pic.twitter.com/xvjTp21Sa2
— Florida’s Voice (@FLVoiceNews) December 19, 2025
“No matter it sells for the world over, the bottom quantity, Germany, UK, anyplace, we are going to match that worth,” Trump mentioned. “Typically it’s 10 occasions greater. We’ve been laughed at, scoffed at for years.”
The offers lengthen Most-Favored-Nation pricing to all state Medicaid packages, anticipated to yield billions in financial savings, whereas requiring the businesses to use related pricing to future medication. Extra income from commerce insurance policies can be repatriated to learn U.S. sufferers, and shoppers can entry steep reductions straight via the TrumpRx program.
Examples embody Gilead Sciences slicing hepatitis C therapy Epclusa from $24,920 to $2,425 per course; Novartis decreasing a number of sclerosis drug Mayzent from $9,987 to $1,137 month-to-month; Sanofi capping insulin at $35 per 30 days; Amgen decreasing ldl cholesterol drug Repatha from $573 to $239; Bristol Myers Squibb dropping HIV remedy Reyataz from $1,449 to $217; and GSK slashing bronchial asthma inhaler Advair Diskus 500/50 from $265 to $89.
The corporations additionally pledged a minimum of $150 billion in U.S. manufacturing investments and donations of energetic pharmaceutical substances to a nationwide strategic reserve.
Florida Republican Rep. Jimmy Patronis praised the transfer, posting: “Individuals shouldn’t be subsidizing the remainder of the world. AMERICA FIRST!”
The White Home mentioned the agreements fulfill Trump’s promise to cease Individuals from paying greater costs to subsidize decrease prices overseas.
